ProtectLife has been honored with the "Product Innovation of the Year Award" at the 2026 Taiwan Biotechnology Industry Awards, recognizing the company's commitment to innovation and its strong in-house research and development capabilities. This achievement highlights the strength and resilience of Taiwan's biotechnology industry while showcasing ProtectLife's dedication to advancing diagnostic technologies. Traditional blood testing often relies on centralized laboratories, requiring larger sample volumes and longer turnaround times. The award-winning ENNOLIFE Clinical Chemistry Analyzer addresses these challenges through a revolutionary point-of-care testing (POCT) platform designed to deliver rapid, accurate, and accessible diagnostic solutions.
Key Features Minimal Sample Volume: Requires only 0.06–0.14 mL of whole blood, significantly reducing the burden of blood collection for patients.
Rapid Turnaround: Delivers accurate test results in as little as 20 minutes, enabling timely clinical decision-making while reducing follow-up visits and communication delays.
Comprehensive Precision: Combines proprietary full-spectrum optical analysis with microfluidic technology to provide high-quality, multi-parameter clinical testing comparable to centralized laboratory standards.
International Regulatory Compliance: Certified under multiple international regulatory frameworks, including Taiwan TFDA, European CE, and U.S. FDA regulatory requirements.
Receiving this national-level recognition reflects ProtectLife's leadership in point-of-care micro-sample diagnostic technologies and reinforces our commitment to advancing healthcare innovation. Looking ahead, we will continue driving technological excellence, supporting better health outcomes across Taiwan, and expanding innovative diagnostic solutions to healthcare providers around the world.
